Home
Biotheus, Inc.

Biotheus, Inc. Market Share Analysis for May 2026

biotheusin the future, biotheus will quickly become the first echelon of domestic biopharmaceutical companies with its high-value product chain, strong innovation capabilities, and experienced core team.

Industry: N/A

Domainbiotheus.com

Year Founded2018

Employees51 - 200

Annual Revenue--

Biotheus, Inc.

Biotheus, Inc. (including company regionals)

biotheus.com

See more website traffic and engagement information

Total visits to Biotheus, Inc.'s top domains

Understand Biotheus, Inc. market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

biotheus.com594

See more with Sales Intelligence

Avg. visit duration in Biotheus, Inc.'s top domains

Analyze Biotheus, Inc. engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

biotheus.com00:00:50

See more with Sales Intelligence

Avg. pageviews on Biotheus, Inc.'s top domains

See how Biotheus, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

biotheus.com2.05

See more with Sales Intelligence

Biotheus, Inc. top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Biotheus, Inc.

These are the website technologies, by industry, used by Biotheus, Inc. top domains

Mobile (2)

Meta Viewport

Advertising (1)

DoubleClick

Conversion & Analytics (1)

Google Analytics

Marketing (1)

Google Marketing Platform

More Technologies

1

See all

News & Signals from Biotheus, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsBiotheus Inc. sells assets to BioNTech US Inc. in the amount of $1.5B.Soon after, BioNTech SE and its partner Bristol Myers Squibb announced a blockbuster $1.5 billion upfront deal for a cancer therapy initially sourced from Chinese startup Biotheus Inc.

NewsMerck KGaA partnered with Biotheus Inc. on Nov 1st '22.Notably, in November 2022, Merck KGaA partnered with Biotheus to optimize the drug approval process within China's biopharmaceutical sector, enhancing labware demand.

NewsBiotheus Inc. is developing novel bispecific antibodies that target hypoxic solid tumors.Biotheus will evaluate Talem Therapeutics' AI-enhanced TATX-20 antibody asset to develop novel bispecific antibodies that target hypoxic solid tumors.